Request Demo
Recent blog posts
Latest Hotspot
8 min read
Monepantel Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Monepantel: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Migraine Prevention Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Migraine Prevention clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Focal Epilepsy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Focal Epilepsy clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
RP-901 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
RP-901: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Lennox-Gastaut Syndrome Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Lennox-Gastaut Syndrome clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
I-022 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
I-022: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Benapenem Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Benapenem: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Recombinant oncolytic virus M1(Guangzhou Vitron) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Recombinant oncolytic virus M1(Guangzhou Vitron): Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Eftilagimod alpha Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
Eftilagimod alpha: Phase 2/3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Dravet Syndrome Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Dravet Syndrome clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
Spinal Muscular Atrophy Clinical Landscape Readout Outlook Report 2026: Endpoints, Sponsors and White Space
17 July 2026
2026 Spinal Muscular Atrophy clinical readout outlook mapping trial endpoints, sponsors, phases, geographies, evidence timing and development white space.
Latest Hotspot
8 min read
GS-100 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
17 July 2026
GS-100: Phase 3. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.